Literature DB >> 23765987

LC-MS3 quantification of O-glycopeptides in human serum.

Miloslav Sanda1, Petr Pompach, Julius Benicky, Radoslav Goldman.   

Abstract

Quantitative analysis of site-specific glycosylation of proteins is a challenging part of glycoproteomic research. Multiple enrichment steps are typically required in the analytical workflows to achieve adequate characterization of the site-specific glycoforms. In spite of recent advances, quantitative workflows need further development. Here, we report a selective and sensitive MS2 followed by further fragmentation in the linear IT-MS analyzer (MS3) multiple reaction monitoring workflow mass spectrometric method for direct analysis of O-glycopeptides in difficult matrix such as serum. Method optimization was performed using two serum glycoproteins, hemopexin (HPX) and sex hormone binding globulin. With the optimized MS3 workflow, we were able to analyze major glycoforms of HPX directly in human serum. Quantification of the minor glycoforms of HPX and glycoforms of sex hormone binding globulin required enrichment of the protein because these analytes were below the sensitivity of the 4000 quadrupole ion trap hybrid mass spectrometer in the complex serum background. In conclusion, we present a quantitative method for site-specific analysis of O-glycosylation with general applicability to mucin-type glycoproteins. Our results document reliable application of the optimized MS3 multiple reaction monitoring workflow to the relative quantification of O-glycosylation microheterogeneity of HPX in human serum. Introduction of isotopically labeled standards would be desirable to achieve absolute quantification of the analytes. The possibility to analyze serum samples directly represents a significant improvement of the quantitative glycopeptide workflows with the potential for use in clinical applications.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  LC-MS3; O-glycosylation; Quantification of glycopeptides

Mesh:

Substances:

Year:  2013        PMID: 23765987      PMCID: PMC3808000          DOI: 10.1002/elps.201200658

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  26 in total

1.  Fibrinogen alpha chain O-glycopeptides as possible markers of urinary tract infection.

Authors:  Tiziana Pacchiarotta; Paul J Hensbergen; Manfred Wuhrer; Cees van Nieuwkoop; Ekaterina Nevedomskaya; Rico J E Derks; Bart Schoenmaker; Carolien A M Koeleman; Jaap van Dissel; André M Deelder; Oleg A Mayboroda
Journal:  J Proteomics       Date:  2011-10-31       Impact factor: 4.044

Review 2.  The current status of clinical proteomics and the use of MRM and MRM(3) for biomarker validation.

Authors:  Jérôme Lemoine; Tanguy Fortin; Arnaud Salvador; Aurore Jaffuel; Jean-Philippe Charrier; Geneviève Choquet-Kastylevsky
Journal:  Expert Rev Mol Diagn       Date:  2012-05       Impact factor: 5.225

3.  Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum.

Authors:  Tujin Shi; Thomas L Fillmore; Xuefei Sun; Rui Zhao; Athena A Schepmoes; Mahmud Hossain; Fang Xie; Si Wu; Jong-Seo Kim; Nathan Jones; Ronald J Moore; Ljiljana Pasa-Tolić; Jacob Kagan; Karin D Rodland; Tao Liu; Keqi Tang; David G Camp; Richard D Smith; Wei-Jun Qian
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

4.  Mining the O-glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines.

Authors:  Catharina Steentoft; Sergey Y Vakhrushev; Malene B Vester-Christensen; Katrine T-B G Schjoldager; Yun Kong; Eric Paul Bennett; Ulla Mandel; Hans Wandall; Steven B Levery; Henrik Clausen
Journal:  Nat Methods       Date:  2011-10-09       Impact factor: 28.547

Review 5.  Recent advances in the MS analysis of glycoproteins: Theoretical considerations.

Authors:  Iulia M Lazar; Alexandru C Lazar; Diego F Cortes; Jarod L Kabulski
Journal:  Electrophoresis       Date:  2010-11-30       Impact factor: 3.535

6.  Semi-automated identification of N-Glycopeptides by hydrophilic interaction chromatography, nano-reverse-phase LC-MS/MS, and glycan database search.

Authors:  Petr Pompach; Kevin B Chandler; Renny Lan; Nathan Edwards; Radoslav Goldman
Journal:  J Proteome Res       Date:  2012-02-06       Impact factor: 4.466

7.  Determination of site-specific glycan heterogeneity on glycoproteins.

Authors:  Daniel Kolarich; Pia H Jensen; Friedrich Altmann; Nicolle H Packer
Journal:  Nat Protoc       Date:  2012-06-07       Impact factor: 13.491

Review 8.  Protein O-glycosylation analysis.

Authors:  Gerhild Zauner; Radoslaw P Kozak; Richard A Gardner; Daryl L Fernandes; André M Deelder; Manfred Wuhrer
Journal:  Biol Chem       Date:  2012-08       Impact factor: 3.915

Review 9.  Glycan labeling strategies and their use in identification and quantification.

Authors:  L R Ruhaak; G Zauner; C Huhn; C Bruggink; A M Deelder; M Wuhrer
Journal:  Anal Bioanal Chem       Date:  2010-03-12       Impact factor: 4.142

10.  Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation.

Authors:  Rita Pinto; Ana S Carvalho; Tim Conze; Ana Magalhães; Gianfranco Picco; Joy M Burchell; Joyce Taylor-Papadimitriou; Celso A Reis; Raquel Almeida; Ulla Mandel; Henrik Clausen; Ola Söderberg; Leonor David
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

View more
  11 in total

1.  Study of structure-dependent chromatographic behavior of glycopeptides using reversed phase nanoLC.

Authors:  Petr Kozlik; Radoslav Goldman; Miloslav Sanda
Journal:  Electrophoresis       Date:  2017-05-17       Impact factor: 3.535

Review 2.  Glycomics and glycoproteomics of membrane proteins and cell-surface receptors: Present trends and future opportunities.

Authors:  Kevin Brown Chandler; Catherine E Costello
Journal:  Electrophoresis       Date:  2016-03-29       Impact factor: 3.535

3.  Data Independent Analysis of IgG Glycoforms in Samples of Unfractionated Human Plasma.

Authors:  Miloslav Sanda; Radoslav Goldman
Journal:  Anal Chem       Date:  2016-09-29       Impact factor: 6.986

4.  Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring.

Authors:  Petra Darebna; Petr Novak; Radek Kucera; Ondrej Topolcan; Miloslav Sanda; Radoslav Goldman; Petr Pompach
Journal:  J Proteomics       Date:  2016-09-16       Impact factor: 4.044

Review 5.  Targeted methods for quantitative analysis of protein glycosylation.

Authors:  Radoslav Goldman; Miloslav Sanda
Journal:  Proteomics Clin Appl       Date:  2015-01-19       Impact factor: 3.494

6.  Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease.

Authors:  Wei Yuan; Miloslav Sanda; Jing Wu; John Koomen; Radoslav Goldman
Journal:  J Proteomics       Date:  2015-01-09       Impact factor: 4.044

7.  LC-MS3 Strategy for Quantification of Carbamazepine in Human Plasma and Its Application in Therapeutic Drug Monitoring.

Authors:  Dongxiao Ma; Zhengchao Ji; Haiwei Cao; Jing Huang; Lei Zeng; Lei Yin
Journal:  Molecules       Date:  2022-02-11       Impact factor: 4.411

8.  Quantification of fucosylated hemopexin and complement factor H in plasma of patients with liver disease.

Authors:  Julius Benicky; Miloslav Sanda; Petr Pompach; Jing Wu; Radoslav Goldman
Journal:  Anal Chem       Date:  2014-10-24       Impact factor: 6.986

9.  Increased sialylation of site specific O-glycoforms of hemopexin in liver disease.

Authors:  Miloslav Sanda; Julius Benicky; Jing Wu; Yiwen Wang; Kepher Makambi; Jaeil Ahn; Coleman I Smith; Peng Zhao; Lihua Zhang; Radoslav Goldman
Journal:  Clin Proteomics       Date:  2016-09-21       Impact factor: 3.988

Review 10.  Recent Advances in Analytical Approaches for Glycan and Glycopeptide Quantitation.

Authors:  Daniel G Delafield; Lingjun Li
Journal:  Mol Cell Proteomics       Date:  2021-02-20       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.